EGFR and non-small cell lung carcinoma: While a small subpopulation of DT cells is reported to maintain viability via IGF-1R signaling in EGFR-mutated NSCLC treated with first EGFR-TKIs14, the current study also demonstrated AXL binding to EGFR and IGF-1R in DT cells treated with osimertinib, and thus AXL activation was greater in DT cells than in the parental cells.